Oncology clinical trials at Murdoch

The Murdoch Oncology Clinical Trial Unit was established in 2012, with the aim of providing West Australian oncology patients and their families the best possible care through research-driven practice. Our current portfolio of trials examine outcomes of conventional and innovative cancer treatments.

  • Cancer is the leading cause of death in Australia, about 1 in 2 Australian men and 1 in 3 Australia women will be diagnosed with cancer by the aged of 85.
  • Clinical trials play an essential role in discovering new and more effective treatments for cancer.
  • Our Oncology Clinical Trials focus on improving care for some of the most common cancers including prostate, breast, colorectal and melanoma.
  • Great strides are being made in understanding cancer and we are working every day to achieving better quality and quantity of life for patients.
  • Providing exceptional care to patients by off ering innovative cancer treatment which may only be available in a clinical trial setting
  • Conducting clinical trials for patients having treatment for a range of cancer types including lung, breast, pancreatic, renal, bladder, oesophageal and stomach cancer
  • Continual improvement of clinical trial processes and alignment with contemporary best practice

A Randomized, Open-label, Phase II Clinical Trial of Relatlimab (anti-LAG-3) plus Nivolumab in Combination with Chemotherapy Versus Nivolumab in combination with Chemotherapy as First-Line Treatment in Patients with Gastric or Gastroesophageal Junction Adenocarcinoma(Open to Recruitment)

A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab versus Placebo in Subjects with High Risk Invasive Urothelial Carcinoma (Open to Recruitment)

Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects with Resected Esophageal, or Gastroesophageal Junction Cancer (Open to Recruitment)

A Phase 3 Randomized Study Comparing Nivolumab and Ipilimumab Combination Vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse (Open to Recruitment)

A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen (Open to Recruitment)

A Randomized Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab Combined with Fluorouracil plus Cisplatin versus Fluorouracil plus Cisplatin in Subjects with Unresectable Advanced, Recurrent or Metastatic Previously Untreated Esophageal Squamous Cell Carcinoma (Open to Recruitment)

A Phase III, Randomized, Double-blind, Placebo Controlled Study of Adagloxad Simolenin (OBI-822)/OBI-821 Treatment for High Risk Early Stage Triple Negative Breast Cancer Patients, defined as Residual Invasive Disease following Neoadjuvant Chemotherapy OR ≥ 4 Positive Axillary Nodes (Open to Recruitment)

A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle-Invasive Bladder Cancer (Opening soon)

LEAP 007
A Phase 3, randomized, double-blind trial of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) in participants with treatment-naive, metastatic non-small cell lung cancer (NSCLC) whose tumors have a tumor proportion score (TPS) greater than or equal to 1% (LEAP-007) (Open to Recruitment)

A Phase 3, Multinational, Randomized, Open-Label Parallel-Arm study of Avelumab (MSB0010718C) In Combination with Axitinib (Inlyta) versus Sunitinib (Sutent) Monotherapy in the First-Line Treatment of Patients with Advanced Renal Cell Carcinoma (Recruitment Closed)

A Randomized, Multicenter, Open-Label, Phase III Trial Comparing Trastuzumab Plus Pertuzumab Plus a Taxane Following Anthracycline Versus Trastuzumab Emtansine Plus Pertuzumab Following Anthracyclines as Adjuvant Therapy in Patients with Operable HER2-Positive Primary Breast Cancer (Recruitment Closed)

A Phase 3 Randomized, Double-Blind, Placebo-controlled Trial of Pembrolizumab (MK3475/SCH900475) in Combination with Etoposide/Platinum (Cisplatin or Carboplatin) for the First-line Treatment of Subjects with Extensive Stage Small Cell Lung Cancer (Recruitment Closed)

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expression High Levels of PD-L1 (Recruitment Closed)

A Phase III, randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a nonsteroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer (Recruitment Closed)

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Nonsteroidal Aromatase Inhibitors (Anastrazole or Letrozole) plus LY2835219, a CDK4/6 Inhibitor, or Placebo in Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Locoregionally Recurrent or Metastatic Breast Cancer with No Prior Systemic Therapy in this Disease Setting (Recruitment Closed)

A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab or Nivolumab in Combination with Oxaliplatin plus Fluoropyrimidine versus Oxaliplatin plus Fluoropyrimidine in Subjects with Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer (Recruitment Closed)

An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus platinum doublet chemotherapy versus platinum doublet chemotherapy in Subjects with Chemotherapy-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) (Recruitment Closed)

An Open-label, Randomized, Phase 3 Study of Nivolumab or Chemotherapy in Subjects with Relapsed Small-Cell Lung Cancer after Platinumbased First Line Chemotherapy (Recruitment Closed)

Clinical Trial of Nivolumab (BMS-936558) Combined with Ipilimumab Followed by Nivolumab Monotherapy as First-Line Therapy of Subjects with Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma (Recruitment Closed)

A Multistage, Phase II Study Evaluating the Safety and Efficacy of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Paclitaxel as First-Line Treatment for Patients with Metastatic Triple-Negative Breast Cancer (Recruitment Closed)

A Phase III, Open-Label, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination with Bevacizumab Versus Sunitinib in Patients with Untreated Advanced Renal Cell Carcinoma (Recruitment Closed)

A Phase 3, Randomized Study of Nivolumab plus Ipilimumab in Combination with Chemotherapy vs Chemotherapy alone as First Line Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC) (Recruitment Closed)

A Phase 3, Multicenter, Multinational, Randomized, Open-Label, Parallel-Arm Study of Avelumab* (MSB0010718c) Plus Best Supportive Care Versus Best Supportive Care Along as a Maintenance Treatment in Patients with Locally Advanced or Metastatic Urothelial Cancer Whose Disease Did Not Progress After Completion of First-Line Platinum Containing Chemotherapy (Recruitment Closed)

Review of Australian Prescribing Practices of Eribulin (Recruitment Closed)

Associate Professor Kynan Feeney - Medical Oncologist
Associate Professor Daphne Tsoi - Medical Oncologist
Dr Sanjay Mukhedkar - Medical Oncologist
Dr Chrissie Whiteley - Senior Clinical Trial Co-ordinator
Rebecca Weselman - Senior Clinical Trial Co-ordinator
Annemarie Naylor - Clinical Trial Co-ordinator
Justine Leon - Clinical Trial Co-ordinator
Sabina Jelinek - Clinical Trials Nurse
Tina Kern - Medical Administrator
Richard Grainger - Clinical Trials Pharmacist
Hannah Lindley - Clinical Trials Pharmacist

Hart NH, Galvao DA, Saunders C, Taaffe DR, Feeney KT, Spry NA, Tsoi D, et al. (2018) Mechanical suppression of osteolytic bone metastases in advanced breast cancer patients: a randomised controlled study protocol evaluating safety, feasibility and preliminary efficacy of exercise as a targeted medicine. Trials. 19, 695.

Chin-Lenn L, De Boer RH, Segelov E, Marx GM, Hughes TM, McCarthy NJ, White SC, Foo SS, Rutovitz JJ, Della-Fiorentina S, Jennens R, Antill YC, Tsoi D, et al. (2018) The impact and indications for Oncotype DX on adjuvant treatment recommendations when third-party funding is unavailable. Asia Pacific Journal of Clinical Oncology. 14, 410-416.

Moehler M, Janjijian J, Adenis A, Aucoin J, Boku N, Chau I, Cleary I, Feeney K, et al. (2017) CheckMate 649: A randomized, multicenter, open-label, phase 3 study of nivolumab (nivo) + ipilimumab (ipi) or nivo + chemotherapy (CTX) vs CTX alone in pts with previously untreated advanced (adv) gastric (G) or gastroesophageal junction (GEJ) cancer. Journal of Clinical Oncology: 35, (suppl. TPS4132).

Hart NH, Newton RU, Spry NA, Taaffe DR, Chambers SK, Feeney KT, et al. (2017) Can exercise suppress tumour growth in advanced prostate cancer patients with sclerotic bone metastases? A randomised, controlled study protocol examining feasibility, safety and efficacy. BMJ Open. 7, e014458.

You may be interested in